Martin Auster
Stock Analyst at Raymond James
(4.34)
# 354
Out of 5,182 analysts
54
Total ratings
60.47%
Success rate
16.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Initiates: Strong Buy | $6 | $2.17 | +176.50% | 1 | Apr 14, 2026 | |
| SYRE Spyre Therapeutics | Initiates: Strong Buy | $80 | $69.24 | +15.54% | 1 | Apr 14, 2026 | |
| EVMN Evommune | Initiates: Strong Buy | $40 | $25.84 | +54.80% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $24.97 | +52.18% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $71.67 | -0.93% | 2 | Oct 30, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $68.32 | +58.08% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $225.12 | +20.38% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $18.90 | +85.19% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $313.79 | +35.12% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $53.98 | +122.30% | 7 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $99 → $105 | $24.28 | +332.45% | 7 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $8.08 | +221.78% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $8.22 | +1,359.85% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $34.93 | +66.05% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $572.85 | -65.79% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.59 | +6,063.52% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $143.83 | -58.28% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $47.48 | +36.90% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $20.42 | +257.49% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $17.54 | +344.70% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.91 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $9.27 | +363.86% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $15.87 | +32.33% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $51.27 | -68.79% | 1 | May 7, 2020 |
Equillium
Apr 14, 2026
Initiates: Strong Buy
Price Target: $6
Current: $2.17
Upside: +176.50%
Spyre Therapeutics
Apr 14, 2026
Initiates: Strong Buy
Price Target: $80
Current: $69.24
Upside: +15.54%
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $25.84
Upside: +54.80%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $24.97
Upside: +52.18%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $71.67
Upside: -0.93%
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $68.32
Upside: +58.08%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $225.12
Upside: +20.38%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $18.90
Upside: +85.19%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $313.79
Upside: +35.12%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $53.98
Upside: +122.30%
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $24.28
Upside: +332.45%
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $8.08
Upside: +221.78%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $8.22
Upside: +1,359.85%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $34.93
Upside: +66.05%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $572.85
Upside: -65.79%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.59
Upside: +6,063.52%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $143.83
Upside: -58.28%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $47.48
Upside: +36.90%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $20.42
Upside: +257.49%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $17.54
Upside: +344.70%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $1.91
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $9.27
Upside: +363.86%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $15.87
Upside: +32.33%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $51.27
Upside: -68.79%